Da-Tong Chu

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo et al. · Journal of Thoracic Oncology · 2011 · 133 citations

Advanced Nsclc, Oncology, Cancer Management +6

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

Yi‐Long Wu, Masahiro Fukuoka, Tony Mok et al. · Lung Cancer · 2013 · 48 citations

Tumor Response, Quality Of Life, Oncology +7

Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer

Da-Tong Chu, Sang-We Kim, Han-Pin Kuo et al. · Lung Cancer · 2007 · 35 citations

Oncology, Health Communication, Cancer Management +8